Should You Buy Canopy Growth Stock Before Feb. 6?

Canopy Growth's shares have plunged in recent years (down 58% in 2025 and 46% in the prior year) and the company remains cash‑hungry, burning more than CA$88 million in operating cash over the past year. In its most recent fiscal quarter to end‑September cannabis net revenue was CA$51 million, up 12% year‑over‑year, and net loss narrowed to CA$1.6 million from CA$128.3 million largely due to lower impairment/restructuring charges and higher other income; however fundamentals and prospects remain weak and regulatory progress in the U.S. has not materialized. With fiscal Q3 2026 results due Feb. 6, the outlook is uncertain and the equity is characterized as highly risky for investors absent a clear path to sustainable profitability.

Analysis

Market structure: Canopy (CGC) is an idiosyncratic loser — equity holders and unsecured suppliers are most hurt while well‑capitalized Canadian LPs and diversified cannabis ETF shorts (e.g., MJ) benefit from continued distress. Persistent revenue growth in low single digits and CA$88M annual operating cash burn signal oversupply in the Canadian rec market and weak pricing power; expect further consolidation and margin compression over 6–24 months.

Risk assessment: Key tail risks are (1) negative: bankruptcy or large goodwill impairments wiping equity (low probability, high impact) and (2) positive: US federal legalization within 12–36 months causing a re‑rating. Near term (days) the Feb 6 earnings release is the primary catalyst; short term (weeks–months) watch quarterly cash burn >CA$25M and working capital metrics; long term (quarters–years) licensing, retail footprint and US access drive valuation.

Trade implications: Tactical short/put exposure into Feb 6 is warranted given high probability of noisy results; implied volatility will spike so prefer put spreads or buying 1–3 month puts 15–25% OTM sized 1–2% portfolio risk. For portfolio rotation, reduce concentrated small‑cap cannabis by ~50% over 30 days and redeploy into higher quality growth (NVDA, NFLX or QQQ) or long cannabis ETF (MJ) to hedge idiosyncratic risk.

Contrarian angles: Market may be overpricing guaranteed failure — if CGC posts two consecutive quarters of near‑break‑even adjusted EBITDA or reduces annualized cash burn below CA$20M, upside could be 50%+ from depressed levels. Consider structured long dated call spreads (9–12 month) financed by selling nearer dated calls if you want optionality without paying elevated near‑term IV; short squeezes are low probability but can cause sharp short‑term reversals.

Key Decisions for Investors

• Establish a tactical short: allocate 1–2% of portfolio short CGC equity or buy 1–3 month puts 20% OTM ahead of Feb 6 earnings; target profit 30% and set a hard stop at 15% adverse move or cover 5–10 trading days after earnings if no new information.
• Pair trade: short CGC 1% vs long MJ (ETFMG Alternative Harvest ETF) 1% for 3 months to isolate idiosyncratic risk; unwind if CGC outperforms MJ by >10% or if MJ falls >15% within 30 days.
• If seeking asymmetric upside, buy a 9–12 month call spread on CGC (buy ATM, sell 50% OTM) sized 0.5–1% of portfolio only after two consecutive quarters of adjusted EBITDA ≥ $0 or quarterly cash burn ≤ CA$5M; this limits premium paid given elevated IV.
• Reduce direct exposure to small‑cap Canadian cannabis names by ~50% within 30 days and reallocate proceeds: 2–3% to NVDA (NVDA) or 2–3% to NFLX (NFLX) for durable secular growth, or into QQQ for broad tech exposure.
• Monitor regulatory and funding catalysts: track (a) US federal legalization bill movement and major state ballot results over next 6–18 months and (b) CGC quarterly cash burn and adjusted EBITDA each quarter; take incremental profits or add protection if cash burn > CA$25M or EBITDA remains negative for two consecutive quarters.